Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Interferon-alpha produces significant decreases in HIV load.

Tavel JA, Huang CY, Shen J, Metcalf JA, Dewar R, Shah A, Vasudevachari MB, Follmann DA, Herpin B, Davey RT, Polis MA, Kovacs J, Masur H, Lane HC.

J Interferon Cytokine Res. 2010 Jul;30(7):461-4. doi: 10.1089/jir.2009.0090.

2.

Zidovudine and lamivudine: results of phase III studies.

Staszewski S.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S57.

PMID:
8595510
3.

Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial.

Goldstein G, Conant MA, Beall G, Grossman HA, Galpin JE, Blick G, Calabrese LH, Hirsch RL, Fisher A, Stampone P, et al.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Mar 1;8(3):279-88.

PMID:
7859140
4.

Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).

Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P; Novavir Study Group.

Antimicrob Agents Chemother. 2002 Jun;46(6):1906-13.

6.

Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection.

Frissen PH, van der Ende ME, ten Napel CH, Weigel HM, Schreij GS, Kauffmann RH, Koopmans PP, Hoepelman AI, de Boer JB, Weverling GJ, et al.

J Infect Dis. 1994 Jun;169(6):1351-5.

PMID:
7910838
7.
8.

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.

Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC, Hirsch MS.

N Engl J Med. 1996 Oct 10;335(15):1091-8. Erratum in: N Engl J Med 1997 Oct 9;337(15):1097.

PMID:
8813039
9.

Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3.

Lewi DS, Suleiman JM, Uip DE, Pedro RJ, Souza RA, Suleiman GS, Accetturi C, Leite OM, Abreu WB, Kalichman AO, Moraes-Filho JP, Motti EF, Pecoraro ML, Makurath MR, Nessly ML, Leavitt RY.

Rev Inst Med Trop Sao Paulo. 2000 Jan-Feb;42(1):27-36.

10.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
11.
13.

Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.

Molina JM, Ferchal F, Chevret S, Barateau V, Poirot C, Morinet F, Modai J.

AIDS. 1994 Jan;8(1):27-33.

PMID:
7912084
14.

Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082.

Katlama C, Carcelain G, Duvivier C, Chouquet C, Tubiana R, De Sa M, Zagury L, Calvez V, Autran B, Costagliola D; ILSTIM.

AIDS. 2002 Oct 18;16(15):2027-34.

PMID:
12370501
15.

A randomized trial of interferon alpha therapy for HIV type 1 infection.

Haas DW, Lavelle J, Nadler JP, Greenberg SB, Frame P, Mustafa N, St Clair M, McKinnis R, Dix L, Elkins M, Rooney J.

AIDS Res Hum Retroviruses. 2000 Feb 10;16(3):183-90.

PMID:
10710206
16.

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

Ann Intern Med. 2001 Dec 4;135(11):954-64.

PMID:
11730396
17.

Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.

French M, Amin J, Roth N, Carr A, Law M, Emery S, Drummond F, Cooper D; OzCombo 2 investigators.

HIV Clin Trials. 2002 May-Jun;3(3):177-85. Erratum in: HIV Clin Trials 2002 Nov-Dec;3(6):following table of contents.

PMID:
12032876
18.

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD, et al.

Ann Intern Med. 1990 May 15;112(10):727-37.

PMID:
1970466
19.
20.

IMMUNOLOGICAL PROFILES IN HIV POSITIVE PATIENTS FOLLOWING HAART INITIATION IN KIGALI, RWANDA.

Twizerimana AP, Mwatha J, Musabyimana JP, Kayigi E, Harelimana Jde D, Karanja SM, Mutesa L.

East Afr Med J. 2014 Aug;91(8):261-6.

PMID:
26862650

Supplemental Content

Support Center